Published in OBGYN and Reproduction Week, February 7th, 2005
Hot flashes occur in up to 85% of menopausal women.
"Completing enrollment in our Phase III Bio-E-Gel trial is an important milestone that brings BioSante one step closer to a new drug application (NDA) and commercialization of Bio-E-Gel," said Stephen M. Simes, BioSante. "We are confident in the potential of Bio-E-Gel to help women better...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of OBGYN and Reproduction Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.